Abstract
Glucocorticoids are widely used anti-inflammatory and immunosuppressive drugs for rheumatoid arthritis (RA). The disease-modifying potential of low to medium doses of glucocorticoids has been reconfirmed in the past decade, and co-administration of DMARDs and glucocorticoids has become standard in many treatment protocols, especially those for early disease stages but also for long-standing RA. The glucocorticoid regimens used range from continuous low doses to intermittent high doses. Studies of the rationale for and clinical use of glucocorticoids as co-therapy with DMARDs in RA have shown that this approach has a place in modern (tight control) treatment strategies, and that glucocorticoid co-therapy has disease-modifying effects during the first 2 years of treatment in patients with early RA. Furthermore, medium and high doses of glucocorticoids are useful for bridging the interval between initiation of DMARDs and onset of their therapeutic effect. Intra-articular glucocorticoids give good local control and have been used in tight control strategies. New glucocorticoid compounds are becoming available for clinical use that might have an enhanced risk:benefit ratio. Better monitoring of glucocorticoid use will also improve this ratio, and help to allay both patient and rheumatologist concerns about treatment-related adverse effects.
Key Points
-
Glucocorticoids have a place in modern (tight control) treatment strategies in rheumatoid arthritis
-
Glucocorticoids have disease-modifying effects during the first 2 years of treatment in early rheumatoid arthritis
-
Medium and high doses of glucocorticoids are useful for bridging the interval between initiation of DMARDs and onset of their therapeutic effect
-
Safe use of glucocorticoids is enabled by adherence to newly developed guidelines, including those for monitoring of adverse effects
-
New glucocorticoid formulations, some in development, offer delayed release, increased local concentrations and reduced adverse metabolic effects, which should improve their risk:benefit ratio
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hench, P. Effects of cortisone in the rheumatic diseases. Lancet 2, 483–484 (1950).
Huscher, D. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 68, 1119–1124 (2009).
Wolfe, F., Caplan, L. & Michaud, K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 54, 628–634 (2006).
Kalla, A. A. & Tikly, M. Rheumatoid arthritis in the developing world. Best Pract. Res. Clin. Rheumatol. 17, 863–875 (2003).
Buttgereit, F. et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 61, 718–722 (2002).
da Silva, J. A. et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann. Rheum. Dis. 65, 285–293 (2006).
Hoes, J. N., Jacobs, J. W., Verstappen, S. M., Bijlsma, J. W. & van der Heijden, G. J. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis. 68, 1833–1838 (2009).
Jacobs, J. W., van Everdingen, A. A., Verstappen, S. M. & Bijlsma, J. W. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 54, 1422–1428 (2006).
Landewé, R. B. et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46, 347–356 (2002).
van Tuyl, L. H. et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann. Rheum. Dis. 69, 807–812 (2010).
van Everdingen, A. A., Siewertsz van Reesema, D. R., Jacobs, J. W. & Bijlsma, J. W. The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies. Arthritis Rheum. 51, 233–238 (2004).
Malysheva, O. A. et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J. Rheumatol 35, 979–985 (2008).
Augustsson, J., Eksborg, S., Ernestam, S., Gullstrom, E. & van Vollenhoven, R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 1462–1466 (2007).
Emery, P. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390–1400 (2006).
Haugeberg, G., Strand, A., Kvien, T. K. & Kirwan, J. R. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch. Intern. Med. 165, 1293–1297 (2005).
Scott, D. L. et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39, 122–132 (2000).
Kirwan, J. R., Bijlsma, J. W., Boers, M. & Shea, B. J. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Systematic Reviews, Issue 1. Art. No.:CD006356. doi: 10.1002/14651858.CD006356 (2007).
Capell, H. A. et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann. Rheum. Dis. 63, 797–803 (2004).
Hansen, M. et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann. Rheum. Dis. 58, 713–718 (1999).
Kirwan, J. & Boers, M. Low dose prednisolone for treatment of RA. Ann. Rheum. Dis. 63, 1533–1534 (2004).
Ninan, J., Smith, M. D., Dugar, M., O'Brien, K. & Ahern, M. Biologic agents—a panacea for inflammatory arthritis or not? Int. J. Rheumatol. 2009, 420759 (2009).
Naumann, L. et al. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment. Ann. Rheum. Dis. 68, 1934–1936 (2009).
Boers, M. et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350, 309–318 (1997).
Kirwan, J. R. et al. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N. Engl. J. Med. 333, 142–146 (1995).
van Everdingen, A. A., Jacobs, J. W., Siewertsz van Reesema, D. R. & Bijlsma, J. W. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med. 136, 1–12 (2002).
Wassenberg, S., Rau, R., Steinfeld, P. & Zeidler, H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 52, 3371–3380 (2005).
Tengstrand, B., Larsson, E., Klareskog, L. & Hafstrom, I. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand. J. Rheumatol. 36, 351–358 (2007).
Barnes, P. J. & Adcock, I. M. Glucocorticoid resistance in inflammatory diseases. Lancet 373, 1905–1917 (2009).
Choy, E. H. et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann. Rheum. Dis. 67, 656–663 (2008).
Goekoop-Ruiterman, Y. P. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146, 406–415 (2007).
Jacobs, J. W. et al. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann. Rheum. Dis. 60, 61–64 (2001).
van der Veen, M. J. & Bijlsma, J. W. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin. Rheumatol. 12, 500–505 (1993).
Choy, E. H., Kingsley, G. H., Khoshaba, B., Pipitone, N. & Scott, D. L. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann. Rheum. Dis. 64, 1288–1293 (2005).
Taylor, W. J., Rajapakse, C. N., Harris, K. A., Harrison, A. A. & Corkill, M. M. Inpatient treatment of rheumatoid arthritis with synacthen depot: a double blind placebo controlled trial with 6 month followup. J. Rheumatol. 26, 2544–2550 (1999).
Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263–269 (2004).
Jacobs, J. W. How to perform local soft-tissue glucocorticoid injections. Best Pract. Res. Clin. Rheumatol. 23, 193–219 (2009).
Jahangier, Z. N. et al. Is radiation synovectomy for arthritis of the knee more effective than intraarticular treatment with glucocorticoids? Results of an eighteen-month, randomized, double-blind, placebo-controlled, crossover trial. Arthritis Rheum. 52, 3391–3402 (2005).
Derendorf, H., Mollmann, H., Gruner, A., Haack, D. & Gyselby, G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin. Pharmacol. Ther. 39, 313–317 (1986).
Habib, G. S. Systemic effects of intra-articular corticosteroids. Clin. Rheumatol. 28, 749–756 (2009).
Hetland, M. L. et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann. Rheum. Dis. 67, 815–822 (2008).
van der Goes, M. C. et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann. Rheum. Dis. doi: 10.1136/ard.2009.124958.
de Nijs, R. N. et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Eng. J. Med. 355, 675–684 (2006).
Homik, J. et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Systematic Reviews, Issue 1. Art. No.:CD001347. doi: 10.1002/14651858.CD001347 (2000).
de Nijs, R. N., Jacobs, J. W., Algra, A., Lems, W. F. & Bijlsma, J. W. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporosis Int. 15, 589–602 (2004).
Singh, G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am. J. Med. 105, 31S–38S (1998).
Thomas, J., Straus, W. L. & Bloom, B. S. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am. J. Gastroenterol. 97, 2215–2219 (2002).
Hooper, L. et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329, 948–958 (2004).
Rostom, A. et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Systematic Review, Issue 4. Art. No.:CD002296. doi: 10.1002/14651858.CD002296 (2002).
Peters, M. J. et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. 61, 1571–1579 (2009).
Peters, M. J. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325–331 (2010).
Poon, M. et al. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis 155, 371–380 (2001).
Dessein, P. H., Stanwix, A. E. & Joffe, B. I. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 4, R5 (2002).
Garcia-Gomez, C. et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur. J. Clin. Invest. 38, 686–692 (2008).
Park, Y. B. et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am. J. Med. 113, 188–193 (2002).
Stuck, A. E., Minder, C. E. & Frey, F. J. Risk of infectious complications in patients taking glucocorticosteroids. Rev. Infect. Dis. 11, 954–963 (1989).
Schneeweiss, S. et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 56, 1754–1764 (2007).
Jain, A., Witbreuk, M., Ball, C. & Nanchahal, J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J. Hand Surg. Am. 27, 449–455 (2002).
van der Goes, M. C. et al. Patients' and rheumatologists' perspectives on glucocorticoids an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 69, 1015–1021 (2009).
van Tuyl, L. H. et al. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis? Ann. Rheum. Dis. 66, 974–976 (2007).
Goekoop-Ruiterman, Y. P. et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann. Rheum. Dis. 66, 1227–1232 (2007).
Stahn, C. & Buttgereit, F. Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol. 4, 525–533 (2008).
Straub, R. H. & Cutolo, M. Circadian rhythms in rheumatoid arthritis: Implications for pathophysiology and therapeutic management. Arthritis Rheum. 56, 399–408 (2007).
Buttgereit, F. et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371, 205–214 (2008).
Rauchhaus, U. et al. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann. Rheum. Dis. 68, 1933–1934 (2009).
Rauchhaus, U., Schwaiger, F. W. & Panzner, S. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res. Ther. 11, R190 (2009).
Barrera, P. et al. Long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis. [abstract L10]. Presented at the American College of Rheumatology (ACR) Scientific Meeting (2008).
Paul-Clark, M. J. et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J. Immunol. 171, 3245–3252 (2003).
Zimmermann, G. R. et al. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res. Ther. 11, R12 (2009).
Schacke, H., Berger, M., Rehwinkel, H. & Asadullah, K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol. Cell. Endocrinol. 275, 109–117 (2007).
Buttgereit, F., Burmester, G. R. & Lipworth, B. J. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365, 801–803 (2005).
Hickling, P., Jacoby, R. K. & Kirwan, J. R. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br. J. Rheumatol. 37, 930–936 (1998).
van der Kooij, S. M. et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann. Rheum. Dis. 68, 914–921 (2009).
Mottonen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568–1573 (1999).
[No authors listed] EMPIRE Rheumatism Council: multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis; results of three years' treatment. Ann. Rheum. Dis. 16, 277–289 (1957).
Goekoop-Ruiterman, Y. P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381–3390 (2005).
Harris, E. D. Jr et al. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J. Rheumatol. 10, 713–721 (1983).
[No authors listed] Joint Committee of the Medical Research Council and Nufied Foundation on Clinical Trials. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 18, 173–188 (1959).
van Schaardenburg, D. et al. Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum. 38, 334–342 (1995).
Suponitskaia, E. V., Smirnov, A. V., Aleksandrova, E. N., Novikov, A. A. & Nasonov, E. L. Effect of small-dose glucocorticoids on the course of early rheumatic arthritis [Russian]. Klin. Med. (Mosk.) 82, 39–42 (2004).
Svensson, B. et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 52, 3360–3370 (2005).
van Gestel, A. M., Laan, R. F., Haagsma, C. J., van de Putte, L. B. & van Riel, P. L. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br. J. Rheumatol. 34, 347–351 (1995).
Acknowledgements
The authors' research work is performed within the framework of Project T1-106 of the Dutch Top Institute Pharma.
Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Contributions
J. N. Hoes researched data for the article, made a substantial contribution to discussions of the content, wrote the manuscript, and participated in editing and review of the manuscript before submission. J. W. G. Jacobs, F. Buttgereit and J. W. J. Bijlsma contributed equally to all the above aspects of the manuscript.
Corresponding author
Ethics declarations
Competing interests
F. Buttgereit is a consultant for, and receives grant support from, Merck and Nitec Pharma, and has received lecture fees from Merck, Mundipharma and Nitec Pharma. J. W. J. Bijlsma is a consultant for Nitec Pharma. J. N. Hoes and J. W. G. Jacobs declare no competing interests.
Rights and permissions
About this article
Cite this article
Hoes, J., Jacobs, J., Buttgereit, F. et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 6, 693–702 (2010). https://doi.org/10.1038/nrrheum.2010.179
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.179
This article is cited by
-
Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
Rheumatology and Therapy (2023)
-
Albumin mediated reactive oxygen species scavenging and targeted delivery of methotrexate for rheumatoid arthritis therapy
Nano Research (2022)
-
Acupoint nanocomposite hydrogel for simulation of acupuncture and targeted delivery of triptolide against rheumatoid arthritis
Journal of Nanobiotechnology (2021)
-
The Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse Model
Pharmaceutical Research (2016)
-
Direct chemotherapeutic dual drug delivery through intra-articular injection for synergistic enhancement of rheumatoid arthritis treatment
Scientific Reports (2015)